Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
homoharringtonine + lisaftoclax + rituximab + prednisone
- Development stage
- Unknown
- Lead developer
- Ascentage Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen is an investigational therapy being evaluated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It consists of **homoharringtonine (HHT)**, a natural cephalotaxine alkaloid that acts as a protein synthesis inhibitor; **lisaftoclax (APG-2575)**, a potent and selective B-cell lymphoma 2 (BCL-2) inhibitor; **rituximab**, an anti-CD20 monoclonal antibody; and **prednisone**, a corticosteroid. The mechanistic rationale for this combination lies in the ability of homoharringtonine to downregulate the anti-apoptotic protein MCL-1, which is a common resistance factor for BCL-2 inhibitors. By combining these agents, the regimen aims to overcome apoptotic resistance and enhance clinical efficacy in patients with aggressive B-cell malignancies. The regimen is currently being studied in a Phase Ib/II trial led by the First Affiliated Hospital of Zhejiang University.
- Brand names
- SynriboRituxanMabTheraDeltasone
- Other names
- HHT + Lisaftoclax + Rituximab + PrednisoneOmacetaxine mepesuccinate + Lisaftoclax + Rituximab + Prednisone
02
Targets
GR (Glucocorticoid receptor)BCL-2 (BCL-2 family)CD20 (B-lymphocyte antigen CD20)PTC (50S ribosomal peptidyl transferase center)
Beyond the preview
Go deeper on homoharringtonine + lisaftoclax + rituximab + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on homoharringtonine + lisaftoclax + rituximab + prednisone.